Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Moleculin Biotech ( (MBRX) ) has provided an update.
Moleculin Biotech announced significant progress in the development of its drug Annamycin, particularly for relapsed or refractory acute myeloid leukemia (AML). The company has received approval for a pivotal Phase 3 trial, with initial data indicating Annamycin’s potential superiority over existing therapies. The accelerated trial timelines and promising preliminary results could enhance Moleculin’s market position and provide substantial value to stakeholders.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead drug, Annamycin, is designed to circumvent multidrug resistance and reduce cardiotoxicity, with current development targeting relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma.
YTD Price Performance: 1.13%
Average Trading Volume: 51,114
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.71M
For a thorough assessment of MBRX stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Apple Settles $95M Class Action Suit and Clears Siri’s Privacy Norms
- Biden Plans One Last Chip Export Curb on Nvidia Before Leaving Office
- 3 Penny Stocks to Watch Now, 1/9/25
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
